)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Alivus Life Sciences
Alivus Life Sciences (ALVUS) investor relations material
Alivus Life Sciences Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary31 Jul, 2026
Executive summary
Q1 FY27 saw revenue of INR 640 crore (₹6,404 million), up 6.4% YoY, with strong non-GPL business growth offsetting a sharp GPL decline, supported by new product launches and robust demand across geographies.
Gross margin improved to 60.2% (up 510 bps YoY) and EBITDA margin to 36.6% (up 650 bps YoY), reflecting favorable product mix and operational efficiencies.
PAT for the quarter was INR 160 crore (₹1,600.76 million), with a PAT margin of 25%.
Chronic therapies (CVS and CNS) contributed 58% to revenue; overall, chronic therapies made up 72% of the top line.
Unaudited financial results for the quarter ended June 30, 2026, were approved by the Board on July 30, 2026.
Financial highlights
Revenue from operations: INR 640 crore (₹6,404.14 million), up 6.4% YoY.
EBITDA: INR 234 crore (₹2,341 million), up 29.1% YoY; EBITDA margin: 36.6%.
PAT: INR 160 crore (₹1,600.76 million); PAT margin: 25%.
Free cash flow: INR 90 crore (₹901 million); cash and equivalents: INR 880 crore (₹8,802 million) as of June 30, 2026.
Company remains debt-free.
Outlook and guidance
Revenue growth guidance for FY27 is 10%-12%, with growth skewed towards H2; EBITDA margin expected to sustain in the 30%-32% range.
GPL business expected to remain flat for FY27, with stronger performance anticipated in H2.
Ongoing investments in capacity expansion and pipeline development are expected to support future growth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Alivus Life Sciences
- FY26 saw strong revenue and margin growth, robust cash flow, and a Rs. 5/share dividend.ALVUS
Q4 25/26 - Record Q3FY26 revenue and margins driven by CDMO growth, Non-GPL strength, and solid outlook.ALVUSQ3 25/26
- Q2 FY26 revenue up 16% YoY, 33% EBITDA margin, strong non-GPL growth, and robust cash flow.ALVUSQ2 25/26
- Q1 FY26 saw revenue and profit growth, margin expansion, and strong cash generation.ALVUSQ1 25/26
- Q2 FY25 revenue and profit fell, but margins improved and H2 FY25 is expected to rebound.ALVUSQ2 24/25
- Q1 FY25 saw 9.7% revenue growth, margin gains, and a regulatory halt at Ankleshwar.ALVUSQ1 24/25
- Q4 revenue up 21.1% YoY, EBITDA margin 32.1%, FY2026 guided for mid-teens volume growth.ALVUSQ4 24/25
- Q3FY25 saw 12% revenue growth, record margins, and strong cash flow, with growth investments prioritized.ALVUSQ3 24/25
Next Alivus Life Sciences earnings date
Q2 26/276 Nov, 2026
Alivus Life Sciences
Next Alivus Life Sciences earnings date
Q2 26/276 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage